The Best Biotech To Buy And Hold
When it comes to the best long-term hold in biotech, this company could be the one – and its efforts related to infectious diseases, including… Read More »The Best Biotech To Buy And Hold
When it comes to the best long-term hold in biotech, this company could be the one – and its efforts related to infectious diseases, including… Read More »The Best Biotech To Buy And Hold
If you only buy one stock, which stock should it be? Based on the hottest themes driving the market now, here are 11 “bullseye” investments… Read More »Set Yourself Up For A Bullseye With These 11 Investments
With demand strong, mortgage rates low, and their stocks trading at low valuations to expected earnings, homebuilders find themselves in a sweet spot. Which homebuilders… Read More »Home Sweet Home
While most dividend payers are pricey, there are still pockets of the income universe where value can be found. Here are five contrarian dividend strategies… Read More »Dividend Investing, On The Contrary
What exactly are mRNA and CRISPR technologies, what diseases can they be used to fight – and what are the best stocks and ETFs for… Read More »Gaining Exposure To mRNA And CRISPR
These three healthcare stocks are eliciting bullish sentiments from analysts, who see significant upside for each from current levels. CLICK HERE.
If you bought any of these 20 stocks with modest dividend yields five years ago and have held on to them since, you might be… Read More »What A Difference 5 Years Has Made For These 20 Stocks’ Dividend Yields
Worried about inflation? In developing an overall inflation fighting – and wealth preservation – strategy, it can pay to think small. CLICK HERE.
Interested in mimicking the options trades of some pro traders? Here’s a look at some of the most interesting mega trades the “smart money” has… Read More »Recent “Smart Money” Mega Trades
While the pandemic triggered a massive sell-off in all types of high-yield securities, this high-yielder used the crash to add a business line with the… Read More »A Post-“Coronacrash” High-Yield Turnaround Play